Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection

Mohammad-Ali Jenabian1,2, Nabila Seddiki1,2,3, Ahmad Yatim1,2, Matthieu Carriere1,2, Anne Hulin4, Mehwish Younas1,2, Elnaz Ghadimi5, Ayrin Kök1,2, Jean-Pierre Routy6, Alain Tremblay7, Jean Sévigny7, Jean-Daniel Lelièvre1,2,3,8, Yves Levy1,2,3,8

1 INSERM U955, Equipe 16, Créteil, France, 2 Faculté de Médecine, Université Paris Est Créteil, Créteil, France, 3 Vaccine Research Institute, Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS) HIV Vaccine Network (AHVN), Créteil, France, 4 Groupe Henri-Mondor Albert-Chénèvière, Laboratory of Pharmacology and Toxicology, Créteil, France, 5 Faculty of Dentistry, McGill University, Montréal, Québec, Canada, 6 Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Québec, Canada, 7 Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHU de Québec, and Département de Microbiologie-Infectiologie et d’Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada, 8 Groupe Henri-Mondor Albert-Chénèvière, Immunologie Clinique, Créteil, France

Abstract

The mechanisms by which Regulatory T cells suppress IL-2 production of effector CD4+ T cells in pathological conditions are unclear. A subpopulation of human Treg expresses the ectoenzyme CD39, which in association with CD73 converts ATP/ADP/AMP to adenosine. We show here that Treg/CD39+ suppress IL-2 expression of activated CD4+ T-cells more efficiently than Treg/CD39−. This inhibition is due to the demethylation of an essential CpG site of the Il-2 gene promoter, which was reversed by an anti-CD39 mAb. By recapitulating the events downstream CD39/adenosine receptor (A2AR) axis, we show that A2AR agonist and soluble cAMP inhibit CpG site demethylation of the Il-2 gene promoter. A high frequency of Treg/CD39+ is associated with a low clinical outcome in HIV infection. We show here that CD4+ T-cells from HIV-1 infected individuals express high levels of A2AR and intracellular cAMP. Following in vitro stimulation, these cells exhibit a lower degree of demethylation of Il-2 gene promoter associated with a lower expression of IL-2, compared to healthy individuals. These results extend previous data on the role of Treg in HIV infection by filling the gap between expansion of Treg/CD39+ in HIV infection and the suppression of CD4+ T-cell function through inhibition of IL-2 production.

Citation: Jenabian M-A, Seddiki N, Yatim A, Carriere M, Hulin A, et al. (2013) Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection. PLoS Pathog 9(4): e1003319. doi:10.1371/journal.ppat.1003319

Editor: Daniel C. Douek, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States of America

Received: August 24, 2012; Accepted: March 6, 2013; Published: April 25, 2013

Copyright: © 2013 Jenabian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by ANRS (Agence Nationale de Recherche contre le SIDA et les hépatites virales). JS receives supports from Canadian Institutes of Health Research (CIHR) and FQR. JPR receives supports from AIDS and Infectious Diseases Network of CIHR, Canadian HIV trial network and CIHR.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yves.levy@hmn.aphp.fr

Introduction

Regulatory T cells (Treg) play a dominant role in self-tolerance, control of autoimmune diseases and control of chronic infections by suppressing effector T cells activation, proliferation and functions [1]. Natural Treg derive from the thymus and are characterized by high levels of IL-2 receptor (CD25) and transcription factor FoxP3 and low levels of IL-7 receptor alpha (CD127) [2–5]. Induced Treg are heterogeneous and their phenotype and frequency vary across different disease states. They include interleukin-10 (IL-10) producing Tr1, transforming growth factor (TGF-ß) expressing Th3 cells [6,7] and also Foxp3+/CD39+ effector/memory Tregs [8].

The imbalance of T cell responses in favor of Treg can hamper efficient effector T cell responses as it has been observed in cancer and certain chronic infections [9]. In acute and chronic phases of HIV infection, a dual role for Treg has been reported due to their expansion [10–12]. Treg can suppress anti-HIV specific CD4+ and CD8 T cell responses by inhibiting cytokine production and cell proliferation [13,14]. Increased Treg frequency at the mucosal site is accompanied by increased immune activation and decreased HIV-specific T-cell responses [15]. However, Treg can have a beneficial role by protecting HIV infected patients either at the primary or chronic phase of infection from the deleterious effects of HIV-induced chronic immune activation [11,16,17]. In HIV controllers, low frequencies of Treg have been associated with effective adaptive immune responses, but also with generalized immune activation and CD4 depletion [18].

Numerous mechanisms of Treg suppression have been reported [1]. These include secretion of inhibitory cytokines (IL-10, TGF-ß or IL-35), induction of apoptosis by IL-2 deprivation, perforin/Granzyme B or by CTLA-4 and GITR interactions pathways [1,19]. Treg also use CD39 (nucleoside triphosphate diphosphorylase-1) and CD73 (ecto-5’-nucleotidase) for their suppressive activity. These ecto-enzymes hydrolyse extra-cellular pools of inflammatory ATP into adenosine diphosphate (ADP) and/or adenosine monophosphate (AMP) to adenosine [20–25]. Extracellular adenosine is known to be an important physiological regulator of the immune response [26,27] by...
Author Summary

Regulatory T cells (Treg) represent a subset of T lymphocytes and have a pivotal role in chronic viral infections and cancer by limiting immune activation. It has been shown that Treg are expanded in chronic HIV infected patients. However, the mechanisms of Treg immune-modulator functions are not clearly known. CD39 is an ectonucleotidase which converts the proinflammatory ATP signal into AMP and the immune-suppressive adenosine in concert with another ecto-enzyme CD73. We have previously reported that CD39/adenosine pathway is involved in AIDS progression. However, the mechanism of Treg immunosuppression through CD39 and its involvement in HIV pathogenesis remains unclear. We report here that Treg/CD39+ inhibits the production of IL-2, a cytokine that stimulates the growth of T lymphocytes, via CD39/Adenosine/cAMP enzymatic pathway. The signals induced by adenosine specific receptor A2AR, increase the intracellular levels of cAMP. We show that cAMP inhibits CpG site demethylation of the il-2 gene promoter. We found that T cells from HIV patients have a higher expression on A2AR as well as intracellular cAMP and a lesser capacity to produce IL-2 upon stimulation than healthy subjects. Our results contribute to elucidate the mechanisms by which Treg suppression occurs during HIV infection.

Inhibiting T cell proliferation and IFN-γ/IL-2 production [28] and these effects are mediated through the adenosine-receptor A2A (A2AR) by stimulating the generation of intracellular cyclic AMP (cAMP) [28]. It has been recently shown that Treg inhibit HIV replication in conventional T cells through cAMP-dependent mechanisms [29]. We have recently evaluated the impact of CD39/adenosine pathway in HIV pathogenesis and reported that expanded Treg/CD39+ in infected patients correlate with immune activation and CD4+ cell depletion [30]. Importantly, we showed that these Treg exerted a strong suppressive effect on effector CD8+ T cell functions and these inhibitory effects were relieved by using an anti-CD39 monoclonal antibody [30].

Here we explored the molecular mechanisms used by Treg/CD39+ cells to mediate their suppressive activity on CD4+ T cell function during HIV infection. Using co-culture experiments, we show that Treg/CD39+ cells inhibit IL-2 mRNA expression in activated effector CD4+ T cells. Importantly, this inhibition was partly reversed when CD39 enzymatic activity was blocked by an anti-CD39 mAb. We reasoned that this effect could be mediated through an epigenetic regulation of IL-2 expression involving cAMP-dependent mechanisms. We found that IL-2 inhibition mediated by Treg/CD39+ was correlated with a decrease in CpG demethylation of the il-2 gene promoter. This effect was reproduced by using A2AR agonist as well as soluble cAMP. We also found that CD4+ T cells from HIV infected patients express high level of cytoplasmic cAMP and exhibit a lower frequency of demethylated CpG site of the il-2 gene promoter following in vitro activation through the T cell receptor, when compared to healthy donors. Accordingly, A2AR expression was higher in ex vivo CD4+ T cells from HIV+ patients as compared to healthy controls. All together, these results make the link between Treg/CD39+ expansion and epigenetic mechanisms of IL-2 regulation.

Results

Treg/CD39+ inhibit IL-2 expression in activated T cells through inhibition of CpG site 1 demethylation of the il-2 gene promoter

We first investigated whether Treg inhibited the expression of IL-2 in autologous anti-CD3 stimulated naïve CD4+ T cells in co-culture experiments (Figure 1A). Naïve CD4+ T cells were labeled with CFSE before co-culture with Treg populations and activated overnight with anti-CD3/28 mAbs. CD4+-CFSElow non-dividing cells were then FACS-sorted and IL-2 mRNAs were quantified by qRT-PCR. As shown in Figures 1B and 1C, Treg/CD39+ and Treg/CD39− inhibited dramatically mRNA IL-2 expression of anti-CD3/28 activated CD4+ T cells, but this effect was more pronounced, in the presence of Treg/CD39+. Interestingly, in the presence of blocking anti-CD39 mAbs [29,31], the suppressive function of Treg/CD39+ was decreased by 25.4% (P<0.05). As expected, these antibodies have no effect in co-cultures with Treg/CD39−. These results show that Treg/CD39+ inhibit, at least partially, the expression of IL-2 through the enzymatic activity of CD39. Moreover, we directly assessed CD39 enzymatic activity and measured ATP catalysis into ADP and AMP by HPLC and we have also quantified inorganic phosphate, which derives ATP hydrolysis. The results demonstrate the catalysis of exogenous ATP into ADP and AMP in the presence of purified Treg/CD39+ but not Treg/CD39−. Interestingly this catalysis was inhibited when an anti-CD39 mAb was added to the cells (Figure S1). We also evaluated the production of Adenosine via CD73 in our co-culture model. A significant increase in extracellular CD73 expression was observed in both naïve CD4 T cells and Tregs upon overnight anti-CD3/28 mAbs stimulation (7±7.3 vs. 22.6±0.9% and 6±5.5 vs. 20.7±5.3, respectively, P<0.05, Figure S2). In line with these data, AMP was converted to adenosine in a specific manner as this conversion was totally inhibited by an inhibitor of CD73 enzymatic activity (6.3±6.4 vs. 0.13±0.3 μM, P<0.05; Figure S3).

Demethylation of the unique specific CpG site 1 in the il-2 gene promoter is essential for inducing IL-2 production by TCR activation [32]. We therefore analyzed the methylation status of the CpG site 1 by the bisulfite genomic sequencing method on DNA extracted from anti-CD3/28 activated CD4+ T cells cultured or not with Treg/CD39+. Sequencing of il-2 promoter gene region of 25–30 clones of each experimental condition was performed. As shown in Figure 1D, in vitro activation of CD4+CD45RA+CD25low naïve cells led to a higher frequency of demethylated CpG site 1 in the il-2 gene promoter as compared to non-activated cells (43 vs. 21%; P=0.01), whereas this effect was inhibited significantly when Treg/CD39+ or A2AR agonists were added to the co-cultures, in the presence of an irrelevant IgG control (26%, P=0.02). However, this inhibitory effect of Treg/CD39+ was partially reversed in the presence of an anti-CD39 mAb (32%, P>0.05). All together these data suggest that Treg/CD39+ suppress IL-2 expression in activated cells at the il-2 gene promoter level.

IL-2 expression in activated CD4+ cells can be modulated by A2AR agonists and antagonists

To assess whether CD39/adenosine pathway is involved in the Treg/CD39+ mediated inhibition of IL-2 expression, we evaluated the effects of the A2AR agonist CGS21680 and A2AR antagonist ZM241385, on IL-2 expression of anti-CD3/CD28 stimulated-CD4+ T cells. We found that CGS inhibited significantly the expression of IL-2 (69±11.5% as compared to DMSO control condition). This effect was partially relieved when the A2AR antagonist ZM was added to cultures of activated CD4+ T cells in the presence of CGS (33±4%; P=0.04 for comparison of CGS and CGS+ZM conditions; Figure 2A). Of note, ZM alone did not alter the expression of IL-2 transcripts of activated CD4+ T cells.

PLOS Pathogens | www.plospathogens.org 2 April 2013 | Volume 9 | Issue 4 | e1003319
Next we looked at the effects of A2AR agonist at the DNA level (Figure 2B). The frequency of demethylated CpG site 1 of the il-2 promoter gene in the presence of anti-CD3/28 was 76% and became 53% in the presence of CGS which corresponded to 30% inhibition of CpG demethylation (Figure 2B). Addition of ZM before adding CGS to activated CD4\(^+\) T cells restored the frequency of demethylated CpG at the same level than activated CD4\(^+\) T cells (70% and 75%, respectively; \(P = \text{NS}\)). No effect of the DMSO as control of the vehicle of CGS and ZM was observed (percentage of demethylation around 75% in activated CD4\(^+\) T cells). These results show that the adenosine pathway is involved in the epigenetic regulation of the expression of the IL-2 gene in activated CD4\(^+\) T cells.

**Modulation of adenyl cyclase expression in stimulated naive CD4\(^+\) cells impacts on IL-2 expression**

In CD39/Adenosine enzymatic cascade, A2AR signaling activates intracellular adenyl cyclase enzyme, which increases intracellular levels of cAMP in conventional T cells [29]. To assess whether adenyl cyclase was involved in CD39-induced inhibition of IL-2 expression, we pre-incubated CD4\(^+\) naive T cells with adenyl cyclase inhibitor ddADA or adenyl cyclase activator forskolin, 30 minutes before anti-CD3/CD28 stimulation. As shown in Figure 3A, forskolin inhibited dramatically the expression of IL-2 transcripts in stimulated cells (97\(\pm\)0.2% inhibition). In contrast, inactivation of adenyl cyclase by ddADA favored IL-2 expression. Accordingly, we found that the frequency of CpG site demethylation of il-2 gene promoter was 42% in ddADA conditions (\(P = 0.02\) for comparison of ddADA and non-activated conditions) while it remains close to non-activated cells in the presence of forskolin (21% and 27%, respectively, \(P = 0.33\); Figure 3B).

**cAMP inhibit T-cell proliferation and IL-2 expression at the promoter level**

To assess the impact of cAMP on CD4\(^+\) T cell proliferation, IL-2 mRNA expression and CpG site demethylation, CD4\(^+\) naive T cells were CFSE labeled and activated with anti-CD3/CD28 mAbs. As shown in a representative experiment performed in triplicate (Figure 4A), cAMP inhibited CD4\(^+\) T cell proliferation in a dose dependent manner (16\(\pm\)16% and 75\(\pm\)5% for 100 and 1000 \(\mu\)M respectively; Figure 4B). Similarly, cAMP inhibited IL-2 mRNA expression in activated CD4\(^+\) T cells a dose dependent manner (39\(\pm\)16% and 67\(\pm\)15% inhibition for 100 and 1000 \(\mu\)M respectively; Figure 4C).
As shown in Figure 4D and as compared to non-activated CD4+ T cells, anti-CD3/CD28 mAbs led to an increase of 26% in the percentages of demethylated CpG site 1 (P = 0.012), while no changes were observed when cAMP (1000 μM) was added to the culture (1% changes from non-stimulated conditions).

Next, we investigated whether the effects of cAMP on IL-2 mRNA expression translated to a decrease in the production of IL-2 by activated CD4+ T cells and if this effect was restricted only to naive CD4+ T cells. For this, naive (N), central (CM), effector memory (EM) as well as terminally differentiated effectors (TE) (Figure 5A) were stimulated with anti-CD3/CD28 mAbs with or without different doses of cAMP. As shown in Figure 5B and C (for one representative experiment and pooled data, respectively), at the highest dose, cAMP inhibited by up to 75% the frequency of N and CM IL-2 producing cells as assessed by ICS assay (Figure 5C). This effect was also notable but less dramatic when cAMP was added to EM or TE (Figure 5C). Interestingly, the frequency of IL-2 producing cells following anti-CD3/CD28 stimulation within these latter subsets was higher than those of N and CM. Accordingly, ex vivo analysis of EM and TE FACS-sorted cells showed that the frequency of CpG site 1 demethylation reached 92–100% (data not shown).

In vitro activated CD4+ cells from HIV+ patients were not able to demethylate il-2 CpG site 1 and produce IL-2 due to their high levels of A2AR and intracellular cAMP. It is well known that in chronic HIV infection, T-cell dysfunction is characterized by reduced IL-2 production [33,34].

**Figure 2. Inhibition of IL-2 production by A2AR induced signals during the activation of naive TCD4+ lymphocytes.** CD4+CD25−CD45RA+ naive T cells were pre-incubated with A2AR agonist CGS 21680 (10 μM) and/or A2AR antagonist ZM 241385 (2 μM). After 6H of anti-CD3/CD28 (2 μg/ml) activation, IL-2 production was evaluated by q-PCR. (A) % of inhibition of IL-2 mRNA expression by A2AR stimulation (pooled data of 3 experiments). (B) Inhibition of demethylation of the unique specific CpG site of il-2 gene promoter was performed by bisulphite modification of DNA following molecular cloning and bulk sequencing on anti-CD3/CD28 (2 μg/ml) activated naive CD4+ T cells pre-incubated with A2AR agonist CGS 21680 (10 μM) and/or A2AR antagonist ZM 241385 (2 μM) in 3 independent experiments. 20–30 colonies were analyzed for each experimental condition. *P<0.05, **P<0.01.

doi:10.1371/journal.ppat.1003319.g002

**Figure 3. Activation of Adenyl cyclase inhibit IL-2 production by naive T.** CD4+CD25−CD45RA+ naive T cells were pre-incubated with the Adenyl cyclase inhibitor 2′,5′-DiDeoxyadenosine (ddADA) (200 μM), or the adenyl cyclase activator Forskolin (2 μM) for 30 mins. After 6H of anti-CD3/CD28 (2 μg/ml) activation, IL-2 production was evaluated by q-PCR. (A) % Inhibition of IL-2 mRNA expression by adenyl cyclase activator (pooled data of 3 experiments). (B) The epigenetic changes on methylation of the unique essential CpG site of il-2 gene promoter. The cells were pre-incubated with ddADA (200 μM) or Forskolin (2 μM) for 6H before anti-CD3/CD28 mAbs activation in 3 independent experiments. 20–30 colonies were analyzed for each experimental condition. 20–30 colonies were analyzed for each experimental condition. *P<0.05, ***P = 0.0001.

doi:10.1371/journal.ppat.1003319.g003
The mechanisms leading to this defect remain unclear. Given our previous results showing that chronically infected HIV patients exhibit high levels of Treg/CD39+ [30], we investigated the potential implication of the CD39/A2AR/cAMP pathway in the regulation of IL-2 expression in CD4+ T cells purified from HIV-1 infected patients.

Figure 6 shows that both naive and memory CD4+ T cells from HIV+ patients express significant higher levels of A2AR mRNA as compared to healthy controls (P<0.05 and P<0.01 respectively; Figure 6A). Ex vivo CD4+ T cells from HIV+ patients (n = 6) exhibit also higher levels of intra-cytoplasmic cAMP (mean 548.3±9.1 fmol/million cells) as compared to controls (n = 6; mean 761.6±29.4 fmol/million cells) (P = 0.002; Figure 6B). Therefore, we quantified IL-2 mRNA expression in purified naive CD4+ T cells from HIV+ART- patients (n = 6) and healthy controls (n = 8) following stimulation in the presence of high doses of anti-CD3/CD28 mAbs (5 µg/ml). As shown in Figure 6C, IL-2 mRNA levels were significantly lower in stimulated CD4+ T cells from HIV+ patients as compared to healthy controls (P = 0.004). In another set of experiments performed on a DNA pool obtained from ex vivo and anti-CD3/CD28 activated CD4+ T cells from HIV+ART- patients and healthy controls (n = 3 per group), the analysis of a large number of molecular clones (43 to 67 clones analyzed in each experimental condition) showed that the frequencies of demethylated CpG site 1 in non-stimulated cells were identical in HIV+ patients and healthy controls (P = 0.45, Figure 6D). Anti-CD3/CD28 activation increased significantly CpG demethylation in HIV+ subjects (P = 0.006 for the...
comparison between *ex vivo* and activated conditions) but not in HIV+ patients (P = 0.67). Importantly, we showed that the status of patients (HIV− and HIV+) is significantly correlated with CpG demethylation of the il-2 promoter gene upon anti-CD3/CD28 activation (P = 0.02). All together these results demonstrate a constitutive high expression of A2AR and cAMP resulting in a clear inhibitory effect on CpG demethylation accompanied by the lack of IL-2 production in HIV+ART- upon anti-CD3/CD28 activation.

**Discussion**

The mechanisms used for Treg’s immunosuppressive function during the course of HIV infection are not completely elucidated. Recently we, and others, have shown an increased CD39 expression by Treg in HIV infected progressors compared to healthy controls [30,35]. Moreover, we have shown that blocking CD39 enzymatic activity increased the production of cytokines by HIV-specific T cells. Genetic analysis of several cohorts of HIV-infected individuals showed a relative protection against the development of AIDS associated with CD39 genetic polymorphism [30]. All together these studies strongly suggest that the CD39/Adenosine/cAMP pathway may play a detrimental role contributing to T cell dysfunction in HIV infection. Data presented here extend our previous results by demonstrating that Treg/CD39+ are potent suppressor of IL-2 production by effector T cells as compared to Treg/CD39−. By recapitulating the steps involved downstream of pericellular adenosine signals, we show that the involvement of the CD39/adenosine/cAMP pathway impacts on il-2 gene promoter by inhibiting the demethylation of the unique specific CpG site 1 in il-2 gene promoter, a seminal event for IL-2 expression in activated CD4+ T cells [32]. Furthermore we show that CD4+ T cells from HIV infected individuals are excessively sensitive to this pathway. Our data demonstrate that CD4+ T cells from HIV infected individuals are partially resistant to demethylation of CpG site 1 following an *in vitro* stimulation with anti-CD3/CD28 mAbs as compared to cells from healthy controls. Likely, this defect is associated with a lower expression of IL-2 by activated CD4+ T cells. Of note, as the majority of CpG site 1 in memory CD4+ T cells is already demethylated (more than 80%), in our *in vitro* anti-CD3/CD28 mAbs stimulation experiments, we used naive CD4+ T cells to be able to study the induced modifications in CpG site.

Treg can induce cAMP in effector T cells by increasing adenosine levels in the microenvironment through CD39 and CD73 ectoenzyme pathways [8,22]. In contrast to CD39 which is expressed on both human and murine Treg, CD73 is found only at the surface of murine Treg and this molecule is mostly absent on human Tregs membrane [8,22,36]. However, it is found in intra cellular compartment of human Tregs [36]. A rapid export of pre-

---

**Figure 5.** cAMP induced inhibition of IL-2 production by CD4+ T cell subsets. (A) Gating strategy. (B) Inhibition of intracellular IL-2 production by cAMP in all anti-CD3/CD28 (2 μg/ml) stimulated sub-populations of CD4+ T cells (representative figure of 5 experiments). (C) % inhibition of intra-cellular IL-2 production (pooled data of 5 experiments) by all CD4+ T cells sub-populations. *P<0.05. doi:10.1371/journal.ppat.1003319.g005
formed CD73 to the surface of T cells due to the activation and its removal from the cell surface by an enzymatic cleavage has been reported [37–39]. Within human T cells, CD73 is mostly expressed by effector CD4 and CD8 cells [40] and might also be present in soluble form in the microenvironment [41]. It has been also shown an up regulation of CD73 mRNA in activated T cells [42]. In line with this observation, overnight co-culture experiments showed an increase CD73 expression at the surface of naïve CD4+ T cells and Tregs upon anti-CD3/CD28 mAbs activation together with the conversion of both ATP and AMP into Adenosine. This molecule may be up regulated in inflammatory conditions and in cancerous tissues accompanied by high enzymatic activity [42–44].

Several studies have shown that adenosine plays an important non-redundant role in the regulation of T-cell activation via its specific A2AR [26,45–47]. Signals induced by agonists of A2AR have an inhibitory effect on INF-γ and IL-2 production by effector T cells [28]. We confirm here our previous data [30] showing that both naïve and memory CD4+ T cells from HIV+ patients vs. healthy controls following anti-CD3/CD28 mAbs activation. To reach the technical limitation due to the low frequency of naïve CD4+ T cells in HIV+ patients, the Clonal analysis was performed on a pool of the extracted DNA from naïve CD4 T cells of HIV+ patients and healthy controls before and after CD3/CD28 mAbs activation. *P<0.05, **P<0.01. doi:10.1371/journal.ppat.1003319.g006

Inhibition of IL-2 Expression by Treg via CD39

Signals induced by A2AR agonists increase intracellular levels of cAMP [28] via activation of intracellular adenyly cyclase [48]. cAMP is known as an inhibitor of several cellular functions and immune responses such as T cell proliferation [49] and IL-2 production [50]. It has been shown in a murine AIDS model [51] and in ex vivo studies that T cells from HIV+ patients [52] exhibit higher levels of intracellular cAMP, resulting in a higher sensitivity of these cells to inhibition by cAMP analogues as compared to uninfected T cells [51,52]. In accordance with this, we show significant increased intracellular cAMP levels in CD4+ T cells from HIV infected patients compared to healthy controls. Our data strongly suggest that the increased expression of cAMP in CD4+ T cells from HIV infected patients impairs IL-2 epigenetics regulation. First, we show that by using soluble cAMP with anti-CD3/CD28 stimulated CD4+ T cells we prevented both CpG site 1 demethylation of the IL-2 gene promoter followed by a decrease in IL-2 mRNA expression. These results help to make the link between pericellular adenosine signals through the purinergic receptor A2AR and dysfunction of Treg target cells in HIV infection.

Signals induced by A2AR agonists increase intracellular levels of cAMP [28] via activation of intracellular adenyly cyclase [48]. cAMP is known as an inhibitor of several cellular functions and immune responses such as T cell proliferation [49] and IL-2 production [50]. It has been shown in a murine AIDS model [51] and in ex vivo studies that T cells from HIV+ patients [52] exhibit higher levels of intracellular cAMP, resulting in a higher sensitivity of these cells to inhibition by cAMP analogues as compared to uninfected T cells [51,52]. In accordance with this, we show significant increased intracellular cAMP levels in CD4+ T cells from HIV infected patients compared to healthy controls. Our data strongly suggest that the increased expression of cAMP in CD4+ T cells from HIV infected patients impairs IL-2 epigenetics regulation. First, we show that by using soluble cAMP with anti-CD3/CD28 stimulated CD4+ T cells we prevented both CpG site 1 demethylation of the IL-2 gene promoter followed by a decrease in IL-2 mRNA expression. These results help to make the link between pericellular adenosine signals through the purinergic receptor A2AR and dysfunction of Treg target cells in HIV infection.

Figure 6. High levels of A2AR and endogenous cAMP in CD4+ T cells from HIV infected patients and lack of IL-2 production. (A) CD45RA+ and CD45RA− CD4+ T cells were purified from the blood of ART-naïve HIV-infected patients (n = 5) and healthy controls (n = 5). A2AR mRNA expression was assessed using qPCR. Horizontal lines correspond to the mean for each data set. (B) CD4+ T cells were purified from the blood of ART-naïve HIV-infected patients (n = 6) and healthy controls (n = 8). Intra-cellular cAMP is measured using the cAMP direct enzyme immunoassay from GE healthcare Biosciences. (C) Purified naïve CD4+ T cells form HIV+ART− patients and healthy controls were stimulated with high doses of anti-CD3/CD28 mAbs (5 μg/ml) during 6H and IL-2 mRNA levels were quantified by RT-PCR. (D) The epigenetic changes on methylation of the unique essential CpG site of the IL-2 gene promoter in naïve CD4+ T cells from HIV+ART− patients vs. healthy controls following anti-CD3/CD28 mAbs activation.
demethylation of the il-2 gene promoter as well as IL-2 mRNA and protein expressions. In line with our results, it has recently been shown in systemic lupus erythematosus, that cAMP has suppressive activity on IL-2 and IL-7 production through epigenetic modifications in IL-2 and IL-7 promoter genes [53,54].

Increased levels of cAMP [20] are mediated by intracellular adenylyl cyclase activity [40] in effector T cells [29,35,56]. cAMP has been described as a key component of Treg mediated suppression [57] and this suppression can be reversed by inhibition of adenylyl cyclase activity [30]. In accordance with these studies, our results demonstrate that the adenylyl cyclase activator forskolin, inhibits totally IL-2 mRNA expression and il-2 specific CpG site 1 demethylation in activated T-cells. In contrast, adenylyl cyclase inhibitor dDAFA favors IL-2 production. These data suggest that Treg suppress IL-2 production through cAMP-dependent mechanism which directly impacts on CpG site 1 demethylation in the promoter regions.

The reason why CD4+ T cells from HIV infected individuals express higher levels of cAMP could be related to indirect or direct pathways. Likely, in the context of HIV infection several pathogenic pathways could favor the generation of adenosine and cAMP such as the generation of extracellular high ATP levels related to chronic activation and inflammation and the increased frequency of Treg/CD39+ in HIV [30]. Moreover, CD4+ T cells exhibit an increase in ATPase activity, a result that was associated with a higher percentage of cells expressing CD39+ [58]. Recently, in a model of acute SIV infection, a high expression of CD39 on CD8+FOXP3+CD25+ T cells was shown in the gut mucosa, a site of intense viral replication and inflammation [59]. On the other hand, Treg can also increase intracellular cAMP in effector T cells using an alternative mechanism, via gap junction, as it has recently been reported [29,57]. These junctions allow intercellular communication between adjacent cells and the passage of ions and other molecules. It has been shown that resting T cells exhibit a low density of these channels. Whether chronically activated CD4+ T cells from HIV infected patients exhibit higher levels these channels warrants further studies.

From a physio-pathological standpoint, cAMP may play a dual role: a deleterious role by reducing HIV-specific antiviral immune responses [56] and T cell dysfunction as shown here and also a role: a deleterious role by reducing HIV-specific antiviral immune responses [56] and T cell dysfunction as shown here and also a role: a deleterious role by reducing HIV-specific antiviral immune responses [56] and T cell dysfunction as shown here and also a role: a deleterious role by reducing HIV-specific antiviral immune responses [56] and T cell dysfunction as shown here.

Inhibition of IL-2 Expression by Treg via CD39

Materials and Methods

Patients and cell isolation

Blood samples from antiretroviral therapy (ART) naïve HIV-infected patients and HIV-negative healthy donors were collected at The Clinical Immunology Department of Henri Mondor Hospital and the Regional Blood Transfusion Centre, Creteil, France. Ethical committee approval and written informed consent from all subjects were obtained before study initiation. Total CD4+ naïve and memory T cells were purified using negative isolations kits from Miltenyi Biotec (Bergisch-Gladbach, Germany) according to the manufacturer’s instructions. Treg/CD39+ and Treg/CD39− populations were FACs sorted using a microFlow cell sorter (Beckman-Coulter). The purity of sorted populations was >95%. Treg cells were defined by CD4+CD25highFoxP3+CD127low T cells as we have previously reported [30].

Co-culture of Treg and naive CD4+ T cells

Facs-sorted CD4+CD45RA+CD25− naïve T cells were stained with 0.5 µM CFSE (Molecular probes, Eugene OR, US) and co-cultured with FACs-sorted Treg/CD39+ or Treg/CD39− at 1:2 ratio, in the presence of 1 µg/mL anti-CD3 and anti-CD28 mAbs (Beckman Coulter, Villepinte, France). Total cell concentration was 3×10⁵/well (96-well plate) in a final volume of 200 µL. In some experimental conditions anti-CD39 mAb (10 µg/ml, clone A1, BioLegend, San Diego, LA) or IgG control was added to the cultures. After 18H, CFSE+ activated but non-divided CD4+CD45RA+CD25− T cells were FAC-sorted, then RNA and DNA extracted (Figure 1A).

Measurement of CD39 ATPase activity

Treg/CD39+ or Treg/CD39− cells (5×10⁴ cells/well) were co-cultured with effector CD4+ T cells (10⁵ cells/well) in the presence or absence of anti-CD39 mAb or control IgG1 mAbs (10 µg/mL) for 2 h. The cells were then washed with a phosphate-free reaction buffer (containing 0.5 mM CaCl₂, 120 mM NaCl, 5 mM KCl, 60 mM glucose, and 50 mM Tris–HCl buffer, pH = 8) and ATPase activity was initiated by the addition of ATP or AMP at a concentration 100 µM in 200 µl of reaction buffer for 120 and 45 min respectively at 37°C. To block the internalization of Adenosine, the cells were pre-incubated for 15 min with the adenosine transporter inhibitor Dipriyamol (Sigma-Aldrich), at a concentration of 10 µM, prior to the addition of ATP or AMP. In some experiments a CD73 inhibitor, adenosine 5’-([β,γ-methylene]) diphosphate (Sigma-Aldrich), was added at a concentration of 100 µM 15 min prior to the addition of ATP or AMP. The released inorganic phosphate by hydrolysis of ATP was measured using the malachite green phosphate detection kit (R&D System, Minneapolis, USA) according to the manufacturer’s instructions. In some experiments the supernatants were frozen (−80°C) until analysis by HPLC. This was done with either an Ultimate 3000 Thermofisher HPLC coupled with a UV detector on a reverse-phase
column [Lichrospher 100-5 RP18 Macherey-Nagel] using a mobile phase gradient from 0 to 20% acetonitrile/50 mM KH2PO4 (pH = 6) containing 10 mM of Tetrabutylammonium phosphate 5 mM [62], or with a Beckman Coulter System Gold HPLC coupled with a UV system gold 160 detector on a reverse-phase column (Phenomenex Luna 3u C18(2) 100A,150 mm×4.6 mm) using a mobile phase composed of 25 mM TBA, 5 mM EDTA, 100 mM KH2PO4/K2HPO4, pH 7.0 and 2% methanol (v/v), at a flow rate of 1 ml/min [63].

Proliferation assays

Different concentrations of cAMP (8-Bromoadenosine 3’,5’-cyclic monophosphate sodium salt, Sigma-Aldrich, Lyon, France) were pre-incubated for 30 min with CFSE labeled naïve CD4+CD45RA+CD25− T-cells. Cells were then cultured in 96-well plates and stimulated with 2 µg/ml of coated anti-CD3 and soluble anti-CD28 mAbs for 5 days. At day 2 of culture, cAMP was added in identical concentrations as day 0. The effect of cAMP on proliferation was evaluated measuring the percentage of CFSElow dividing cells.

In some experiments, CD4+CD45RA+CD25− cells were pre-incubated with different reagents: 10 µM adenosine receptor agonist CGS 21680 (Sigma-Aldrich, Lyon, France) or 2 µM adenosine receptor antagonist ZM 241385 (Tocris bioscience, incubated for 30 min with CFSE labeled naïve monophosphate sodium salt, Sigma-Aldrich, Lyon, France) were pre-incubated with ATP or 45 min with 100 µM of coated anti-CD3 and soluble anti-CD28 mAbs for 5 days. At day 2 of culture, cAMP was added in identical concentrations as day 0. The effect of cAMP on proliferation was evaluated measuring the percentage of CFSElow dividing cells.

Statistical analysis

The non-parametric Mann-Whitney U, Fisher’s exact and paired T tests were used for statistical analyses (GraphPad Prism 5.0 statistical software). A P value <0.05 was considered as significant.

Supporting Information

Figure S1 Differential ATPase activity of Treg/CD39+ or Treg/CD39−. FACS-sorted Treg/CD39+ or Treg/CD39− cells were co-cultured with effector CD4+ T cells in the presence or absence of anti-CD39 mAb or control IgG1 (10 µg/ml) for 2 h. The cells were then washed with a phosphate-free reaction buffer and ATPase activity was initiated by the addition of ATP at a concentration 100 µM in 200 µl of the phosphate free reaction buffer for 15 min at 37°C. The released inorganic phosphate by hydrolysis of ATP was measured using the malachite green phosphate detection kit (R&D System, Minneapolis, USA) according to the manufacturer’s instructions. Histograms represent Treg/CD39+ capacity to hydrolyse ATP comparing to Treg/CD39−. CD39 mAb inhibits the ATPase activity of CD39 in a specific manner (pooled data of 4 independent experiments, * P<0.05).

(TIF)

Figure S2 Increase of CD73 expression following overnight anti-CD3/28 mAbs stimulation. FACS-sorted naïve CD4+ T cells and Treg/CD39+ cells were activated separately by anti-CD3 and anti-CD28 mAbs (1 µg/ml). After 18H of activation, the cells were washed and stained by anti-CD73 mAb. (A) A representative figure of 5 independent experiments showing an increase of CD73 expression upon anti-CD3/CD28 mAbs stimulation. (B) Histograms represent the increase of CD73 expression upon overnight anti-CD3/CD28 mAbs stimulation. (pooled data of 5 independent experiments * P<0.05).

(TIF)

Figure S3 Hydrolysis of ATP or AMP into Adenosine in a co-culture of Treg/CD39+ and naïve CD4 T cells. FACS-sorted Treg/CD39+ or Treg/CD39− cells were co-cultured with anti-CD3/28 mAbs stimulated naïve CD4+ T cells in the presence of 10 µM Dipryidamole to block the transport of Adenosine inside T cells prior to addition of 100 µM ATP or AMP, in 200 µl of RPMI. The cells were incubated for 120 min. with ATP or 45 min with AMP at 37°C, then the hydrolysis of exogenous ATP measured by HPLC. (A) A representative HPLC profile of 4 DNA was bisulfite converted using EpTect Kit (Qiagen, Duesseldorf, Germany) according to the manufacturer’s instructions. The unique essential CpG site (site 1) in the il-2 gene promoter [32] was amplified by a PCR (forward GGAAAAATGTGTATATAGAGG, reverse: TTCCCTCTCTAATACTCTTTAA) followed by a nested-PCR (forward GGAAAAATGTGTATATAGAGG, reverse: ATAAATATAAAATAAATCTCTCCTC). A clonal assay was performed for each experimental condition. Briefly, nested-PCR products were used for cloning into a pCR4-TOPO TA plasmid kit (Invitrogen, Carlsbad, CA, USA) and transfected in Escherichia coli according to the manufacturer’s instructions. Colonies were grown on Luria-Bertani (LB) plates overnight at 37°C. Clones screening was done using PureLink Quick Plasmid Miniprep Kit (Invitrogen, Carlsbad, CA, USA) and plasmid DNA was prepared for sequencing analysis. Sequence analyses were done with SeqScape software (Applied Biosystems, Foster City, CA, USA) on at least 25–30 clones from each sample.
References

1. Vignali DA, Collison LW, Workman CJ (2006) How regulatory T cells work. Nat Rev Immunol 6: 529–532.

2. Fehervari Z, Sakaguchi S (2004) Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol 16: 203–208.

3. O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10: 801–805.

4. Liu W, Pumain AL, Xie Y, Zou GL, Lee MK, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701–1711.

5. Sédikdi N, Sanver-Nanan B, Martinson J, Zanders J, Saxon S, et al. (2006) Expression of interleukin-2 (IL-2) and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693–1700.

6. Weiner HL (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207–214.

7. Vieira PL, Christensen JR, Minaee S, O’Neill EJ, Barrat FJ, et al. (2004) Expression of IL-10-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 302: G447–459.

8. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257–1265.

9. Bluestone JA (2011) The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 365: 2129–2139.

10. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, et al. (2004) Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4+ T-cell responses in HIV-infected patients. Blood 104: 3249–3256.

11. Kared H, Leclerc JD, Donka-Petrini V, Aouba A, Melica G, et al. (2008) Human T-cell regulatory T cells are associated with higher CD4+ cell counts in primary infection. AIDS 22: 2451–2460.

12. Bi X, Suzuki Y, Gaitanaz H, Oka S (2009) High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-infected patients with low CD4 counts. Eur J Immunol 39: 301–309.

13. Aandahl EM, Michaelson J, Moretto WJ, Hecht FM, Nixon DF (2004) Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454–2459.

14. Kinter AL, Hernandez M, Bell A, Kern S, Liu Y, et al. (2004) CD25(+)CD4+ regulatory T cells from the periphery blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T-cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.

15. Shaw MJ, Hunt PW, Crichtliff JW, McComb DL, Garcia JC, et al. (2011) Increased frequency of regulatory T cells accompanies increased immune activation in recurrent infection of HIV-positive noncontrollers. J Virol 85: 11422–11434.

16. Belkaid Y, Rouse BT (2005) Natural regulatory T cells in infectious disease. Nat Immunol 6: 353–360.

17. Fazekas de St Groth B, Landay AL (2008) Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 22: 671–683.

18. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatanu H, et al. (2011) A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6: e15924.

19. Sakaguchi S, Miyauchi M, Costantino CM, Hafer DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490–500.

20. Kazemzadeh E, Kozik J, Sevigny J, Siegel JB, Amrhein J, et al. (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271: 33116–33122.

21. Kukukli F, Levesque SA, Sevigny J (2011) Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol 66: 263–299.

22. Borselli G, Kleinewefelder M, Di Mini D, Stergiak A, Diamantini A, et al. (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225–1232.

23. Dayer KM, Deaglio S, Gao W, Friedman D, Strom TB, et al. (2007) CD39 and control of cellular immune responses. Partenogenetica 5: 171–180.

24. Pule ED, Brockman MJ, Olson KE, Dreespałus JH, Kiwee JR, et al. (2007) CD39/NTPase-1 activity and expression in normal leukocytes. Thromb Res 121: 309–317.

25. Fauchier M, Lecka J, Soliman E, Kaufmann G, Pelteier J, et al. (2012) Coexpression of ecto-5′-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 302: G447–459.

26. Ohta A, Sitkowski M (2003) Role of G-protein-coupled adenose receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916–920.

27. Sitkowski MV, Lukacsek D, Apasov S, Kojima H, Koshiba M, et al. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenose A3A receptors. Annu Rev Immunol 22: 657–682.

28. Ohta A, Matsu A, Kini R, Subramanian M, Goel N, et al. (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183: 5487–5495.

29. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA (2011) Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 117: 5372–5380.

30. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, et al. (2011) Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One 6: e14029.

31. Murayama A, Sakurai K, Nakama M, Yasuzawa-Tanaka K, Fujita E, et al. (2006) A specific GpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. Endo J 25: 1081–1092.

32. Porichi F, Kaufmann DE (2011) HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 6: 174–180.

33. Younes SA, Yassin-Diab B, Dumont AR, Boulad MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909–1922.

Inhibition of IL-2 Expression by Treg via CD39

Author Contributions

Conceived and designed the experiments: MAJ NS YL. Performed the experiments: MAJ AY MY MG AH AK AT. Analyzed the data: MAJ NS JDL YL EG JPR JS. Contributed reagents/materials/analysis tools: JDL JPR JS. Wrote the paper: MAJ NS YL.
33. Schule Zur Wiesch J, Thomassen A, Hartjen P, Toth I, Lehmann C, et al. (2011) Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 85: 1287–1297.

34. Manelapahal M, Szczerpanski MJ, Szajuk M, Ren J, Lenner DE, et al. (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15: 6348–6357.

35. Airas L, Niemela J, Salmin M, Paarumenn T, Smith DJ, et al. (1997) Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol 136: 421–431.

36. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, et al. (2009) Increased CD73 expression on CD8+ T cells of HIV infected patients. J Immunol 182: 5954–5962.

37. Klein M, Vaeth M, Schuel T, Grabbe S, Baumgrass R, et al. (2011) Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol 188: 1091–1097.

38. Liang B, Workman C, Lee J, Chew C, Dale BM, et al. (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180: 5916–5926.

39. Thomson LF, Ruech JM, Glass A, Moldenhauer G, Moller P, et al. (1990) Increased expression of programmed cell death protein CD73 on the surface of lymphocytes from patients with systemic lupus erythematosus. J Biol Chem 265: 14347–14346.

40. Yegutkin G, Bodin P, Burnstock G (2000) Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5'-nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 129: 921–926.

41. Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, et al. (2009) Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). Tissue Antigens 35: 9–19.

42. Erdmann AA, Gao ZG, Rowlett RM, Reuter BK, Wiznerowicz E, et al. (2009) CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 199: 494–504.

43. Zhang B (2010) CD73: a novel target for cancer immunotherapy. Cancer Res 70: 6407–6411.

44. Jin D, Fan J, Wang L, Thompson LF, Liu A, et al. (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70: 2245–2253.

45. Huang S, Apasov S, Koshiba M, Sitkovsky M (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. J Immunol 159: 4707–4714.

46. Hedrich CM, Rauen T, Tsokos GC (2011) cAMP responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem 286: 43437–43446.

47. Pfleghar J, Kukulski F, Levesque SA, Lavoie EG, Lecka J, et al. (2005) CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 199: 494–504.

48. Kammer GM (1988) Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 115: 88–99.

49. Kammer GM, Aandahl EM, Trehak M, Boniver J, Tasken K, et al. (2001) Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to retrovirus-induced immunodeficiency of mice (MAIDS): a useful in vivo model for drug testing. FASEB J 15: 1466–1468.

50. Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, et al. (2009) Increased expression of programmed cell death protein CD73 on the surface of lymphocytes from patients with systemic lupus erythematosus. J Biol Chem 265: 14347–14346.

51. Rahmouni S, Aandahl EM, Tasken K, et al. (2001) Increased expression of programmed cell death protein CD73 on the surface of lymphocytes from patients with systemic lupus erythematosus. J Biol Chem 286: 43437–43446.

52. Bopp T, Becker G, Klein M, Klein-Heiling S, Palmetschöfer A, et al. (2007) Cyclic adenosine monophosphate is a key component of regulatory T-cell-mediated suppression. J Exp Med 204: 1303–1310.

53. Leal DB, Srecher CA, Bertoncelle C, Garli LF, Leal CA, et al. (2003) HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta 1746: 129–134.

54. Nigam P, Velu V, Kammanganat S, Chennareddi L, Kwa S, et al. (2010) Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T-cell response and viral control. J Immunol 184: 1690–1701.

55. Navarro J, Panzon G, Jimenez JL, Fernandez-Cruz E, Pizarro A, et al. (1998) Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol 72: 4712–4720.

56. Raaschig HK, Bba JC, Furuta GT, Leonard MO, Jacobson KA, et al. (2003) Coordinated adenosine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198: 783–796.

57. Rushmore TH, Levesque SA, Lavoie EG, Lecka J, Bigonnese F, et al. (2005) Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1: 193–204.